David S Gierada1, Paul F Pinsky2, Fenghai Duan3, Kavita Garg4, Eric M Hart5, Ella A Kazerooni6, Hrudaya Nath7, Jubal R Watts7, Denise R Aberle8. 1. Mallinckrodt Institute of Radiology, Washington University School of Medicine, Box 8131, 510 S. Kingshighway Blvd., St. Louis, MO, 63110, USA. gieradad@wustl.edu. 2. National Cancer Institute, 9609 Medical Center Drive, Room 5E108, Bethesda, MD, 20892, USA. 3. Department of Biostatistics and Center for Statistical Sciences, Brown University School of Public Health, Providence, RI, 02912, USA. 4. University of Colorado School of Medicine, Mail Stop F726, Box 6510, Aurora, CO, 80045, USA. 5. Department of Radiology, Northwestern University Feinberg School of Medicine, 676 N. Saint Clair, Suite 800, Chicago, IL, 60611, USA. 6. Department of Radiology, University of Michigan Health System, Cardiovascular Center, Room #5482, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA. 7. Department of Radiology-JTN370, University of Alabama at Birmingham School of Medicine, 619 19th Street South, Birmingham, AL, 35233, USA. 8. Department of Radiological Sciences, David Geffen School of Medicine at UCLA, 924 Westwood Boulevard, Suite 420, Los Angeles, CA, 90024, USA.
Abstract
OBJECTIVES: This study retrospectively analyses the screening CT examinations and outcomes of the National Lung Screening Trial (NLST) participants who had interval lung cancer diagnosed within 1 year after a negative CT screen and before the next annual screen. METHODS: The screening CTs of all 44 participants diagnosed with interval lung cancer (cases) were matched with negative CT screens of participants who did not develop lung cancer (controls). A majority consensus process was used to classify each CT screen as positive or negative according to the NLST criteria and to estimate the likelihood that any abnormalities detected retrospectively were due to lung cancer. RESULTS: By retrospective review, 40/44 cases (91%) and 17/44 controls (39%) met the NLST criteria for a positive screen (P < 0.001). Cases had higher estimated likelihood of lung cancer (P < 0.001). Abnormalities included pulmonary nodules ≥4 mm (n = 16), mediastinal (n = 8) and hilar (n = 6) masses, and bronchial lesions (n = 6). Cancers were stage III or IV at diagnosis in 32/44 cases (73%); 37/44 patients (84%) died of lung cancer, compared to 225/649 (35%) for all screen-detected cancers (P < 0.0001). CONCLUSION: Most cases met the NLST criteria for a positive screen. Awareness of missed abnormalities and interpretation errors may aid lung cancer identification in CT screening. KEY POINTS: • Lung cancer within a year of a negative CT screen was rare. • Abnormalities likely due to lung cancer were identified retrospectively in most patients. • Awareness of error types may help identify lung cancer sooner.
OBJECTIVES: This study retrospectively analyses the screening CT examinations and outcomes of the National Lung Screening Trial (NLST) participants who had interval lung cancer diagnosed within 1 year after a negative CT screen and before the next annual screen. METHODS: The screening CTs of all 44 participants diagnosed with interval lung cancer (cases) were matched with negative CT screens of participants who did not develop lung cancer (controls). A majority consensus process was used to classify each CT screen as positive or negative according to the NLST criteria and to estimate the likelihood that any abnormalities detected retrospectively were due to lung cancer. RESULTS: By retrospective review, 40/44 cases (91%) and 17/44 controls (39%) met the NLST criteria for a positive screen (P < 0.001). Cases had higher estimated likelihood of lung cancer (P < 0.001). Abnormalities included pulmonary nodules ≥4 mm (n = 16), mediastinal (n = 8) and hilar (n = 6) masses, and bronchial lesions (n = 6). Cancers were stage III or IV at diagnosis in 32/44 cases (73%); 37/44 patients (84%) died of lung cancer, compared to 225/649 (35%) for all screen-detected cancers (P < 0.0001). CONCLUSION: Most cases met the NLST criteria for a positive screen. Awareness of missed abnormalities and interpretation errors may aid lung cancer identification in CT screening. KEY POINTS: • Lung cancer within a year of a negative CT screen was rare. • Abnormalities likely due to lung cancer were identified retrospectively in most patients. • Awareness of error types may help identify lung cancer sooner.
Authors: Satinder Singh; Paul Pinsky; Naomi S Fineberg; David S Gierada; Kavita Garg; Yanhui Sun; P Hrudaya Nath Journal: Radiology Date: 2011-01-19 Impact factor: 11.105
Authors: Ernst Th Scholten; Nanda Horeweg; Harry J de Koning; Rozemarijn Vliegenthart; Matthijs Oudkerk; Willem P Th M Mali; Pim A de Jong Journal: Eur Radiol Date: 2014-09-04 Impact factor: 5.315
Authors: David S Gierada; Thomas K Pilgram; Melissa Ford; Richard M Fagerstrom; Timothy R Church; Hrudaya Nath; Kavita Garg; Diane C Strollo Journal: Radiology Date: 2007-11-16 Impact factor: 11.105
Authors: Linda L Humphrey; Mark Deffebach; Miranda Pappas; Christina Baumann; Kathryn Artis; Jennifer Priest Mitchell; Bernadette Zakher; Rongwei Fu; Christopher G Slatore Journal: Ann Intern Med Date: 2013-09-17 Impact factor: 25.391
Authors: Nanda Horeweg; Ernst Th Scholten; Pim A de Jong; Carlijn M van der Aalst; Carla Weenink; Jan-Willem J Lammers; Kristiaan Nackaerts; Rozemarijn Vliegenthart; Kevin ten Haaf; Uraujh A Yousaf-Khan; Marjolein A Heuvelmans; Erik Thunnissen; Matthijs Oudkerk; Willem Mali; Harry J de Koning Journal: Lancet Oncol Date: 2014-10-01 Impact factor: 41.316
Authors: David S Gierada; Paul Pinsky; Hrudaya Nath; Caroline Chiles; Fenghai Duan; Denise R Aberle Journal: J Natl Cancer Inst Date: 2014-10-18 Impact factor: 13.506
Authors: Asha Bonney; Reem Malouf; Corynne Marchal; David Manners; Kwun M Fong; Henry M Marshall; Louis B Irving; Renée Manser Journal: Cochrane Database Syst Rev Date: 2022-08-03
Authors: Douglas E Wood; Ella A Kazerooni; Scott L Baum; George A Eapen; David S Ettinger; Lifang Hou; David M Jackman; Donald Klippenstein; Rohit Kumar; Rudy P Lackner; Lorriana E Leard; Inga T Lennes; Ann N C Leung; Samir S Makani; Pierre P Massion; Peter Mazzone; Robert E Merritt; Bryan F Meyers; David E Midthun; Sudhakar Pipavath; Christie Pratt; Chakravarthy Reddy; Mary E Reid; Arnold J Rotter; Peter B Sachs; Matthew B Schabath; Mark L Schiebler; Betty C Tong; William D Travis; Benjamin Wei; Stephen C Yang; Kristina M Gregory; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2018-04 Impact factor: 11.908